The European Federation of Pharmaceutical Industries and Associations (EFPIA) has issued a statement criticizing the withdrawal agreement released on 14 November that outlines the U.K.'s exit (Brexit) from the European Union in 2019.
The document does not protect patient safety and public health, the EFPIA said.
"The withdrawal agreement fails to specifically address the health issues important to patients, their safety, and the wider public health," Director General Nathalie Moll noted in a statement. "While we welcome the commitment to create a 'free trade area combining deep regulatory and customs cooperation' referred to in the political declaration, its failure to contain an explicit reference to the importance of securing long-term, extensive cooperation around the regulation of medicines is not in the best interest of patients."
